A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism

Trial Profile

A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Apixaban (Primary) ; Enoxaparin sodium; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AMPLIFY
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 09 Feb 2017 Results of post hoc analysis assessing abnormal vaginal bleeding in women with venous thromboembolism published in the Thrombosis and Haemostasis.
    • 12 Sep 2016 Results of this and two other trials (AMPLFY-J and AMPLIFY-EXT) published in the Drugs (2016).
    • 01 Sep 2016 Results of post-hoc analysis published in the Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top